CAJ | 학술논문

目的：探讨英夫利西单抗联合免疫抑制剂维持治疗中重度溃疡性结肠炎（UC）的临床疗效。方法36例UC患者均经使用英夫利西单抗5 mg·kg-1于第0、2和6周诱导进入缓解期后，将其按用药的不同分为3组：治疗组、对照组和联合治疗组，每组12例。治疗组采用注射用英夫利西单抗治疗，对照组采用硫唑嘌呤治疗，联合治疗组采用注射用英夫利西单抗联合硫唑嘌呤治疗。观察3组临床疗效的情况。结果治疗组、联合治疗组缓解率分别为66.7%、58.3%和总有效率分别为91.7%、91.7%，均明显高于对照组的25.0%、58.3%（均P＜0.05）；治疗组缓解率、总有效率与联合治疗组比较差异均无统计学意义（均P＞0.05）。结论英夫利西单抗联合免疫抑制剂维持治疗中重度UC疗效显著，无明显的不良反应，可作为治疗中重度UC的选择方案之一。
목적：탐토영부리서단항연합면역억제제유지치료중중도궤양성결장염（UC）적림상료효。방법36례UC환자균경사용영부리서단항5 mg·kg-1우제0、2화6주유도진입완해기후，장기안용약적불동분위3조：치료조、대조조화연합치료조，매조12례。치료조채용주사용영부리서단항치료，대조조채용류서표령치료，연합치료조채용주사용영부리서단항연합류서표령치료。관찰3조림상료효적정황。결과치료조、연합치료조완해솔분별위66.7%、58.3%화총유효솔분별위91.7%、91.7%，균명현고우대조조적25.0%、58.3%（균P＜0.05）；치료조완해솔、총유효솔여연합치료조비교차이균무통계학의의（균P＞0.05）。결론영부리서단항연합면역억제제유지치료중중도UC료효현저，무명현적불량반응，가작위치료중중도UC적선택방안지일。
Objective To investigate the curative effect of maintenance treatment with infliximab and immunosuppressant on moderate to severe ulcerative colitis (UC). Methods Thirty-six patients with UC were given infliximab 5 mg·kg-1 for the induction of remission at week 0,2 and 6.After entering remission, patients were treated with infliximab (treatment group, n=12), azathioprine (control group, n=12) or combination of both(combined treatment group, n=12). Clinical efficacy was compared among the three groups. Results The remission rate and total effective rate in control group (25.0% and 58.3%, respectively) were significantly lower than those in treatment group (66.7%and 91.7%, respectively) and combined treatment group (58.3%and 91.7%,respectively)(P<0.05).There were no significant differences between treatment group and combined treatment group (P>0.05).Conclusion The maintenance treatment with infliximab and immunosuppressant is an effective option for treating moderate to severe UC and does not cause obvious adverse reactions.